homemarket NewsLupin shares dip 2% after CLSA cuts earnings per share estimate by 9 16% for FY23 25

Lupin shares dip 2% after CLSA cuts earnings per share estimate by 9-16% for FY23-25

Lupin share price: Shares of Lupin fell as much as two percent on Thursday after CLSA slashed its earnings per share estimate for the pharmaceutical company by 9-16 percent for FY23-25. The brokerage firm also cut its target price on the stock to Rs 640 from Rs 660.

Profile image

By CNBCTV18.com Jun 30, 2022 1:05:33 PM IST (Updated)

Listen to the Article(6 Minutes)
Shares of Lupin fell as much as 2 percent on Thursday after CLSA slashed its earnings per share (EPS) estimate for the pharmaceutical company by 9-16 percent for FY23-25.

Share Market Live

View All

The brokerage firm also cut its target price on the stock to Rs 640 from Rs 660.
At 1246 IST, shares of Lupin fell 1.7 percent at Rs 609.65 on the BSE. The scrip was about 5 percent away from its 52-week low of Rs 583.05.
Also Read |
The cut in EPS and target price was largely because CLSA thinks that margin stress is mainly due to underutilised capacities for the US market. It further believes that Lupin will need to take tough decisions like shutting down sites and ironing out redundancies.
The US launches in the second half. which are subject to the approval of the US Food and Drug Administration, can lead to better overhead absorption, CLSA said. The contribution of some of those big launches is only for a limited timeframe, it added.
Lupin, the world’s tenth-largest generic pharma company, has 15 state-of-the-art manufacturing facilities spread across India, the US, Brazil, and Mexico.

Most Read

Share Market Live

View All
Top GainersTop Losers
CurrencyCommodities
CurrencyPriceChange%Change